Home Cart Sign in  
Chemical Structure| 2230198-02-2 Chemical Structure| 2230198-02-2

Structure of Danuglipron
CAS No.: 2230198-02-2

Chemical Structure| 2230198-02-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

PF-06882961 is a GLP-1R agonist. It works as a candidate drug for treatment for Type 2 Diabetes Mellitus in Phase 2 study.

Synonyms: PF-06882961

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Danuglipron

CAS No. :2230198-02-2
Formula : C31H30FN5O4
M.W : 555.59
SMILES Code : O=C(C1=CC=C2N=C(CN3CCC(C4=NC(OCC5=CC=C(C#N)C=C5F)=CC=C4)CC3)N(C[C@H]6OCC6)C2=C1)O
Synonyms :
PF-06882961
MDL No. :MFCD32661373
InChI Key :HYBAKUMPISVZQP-DEOSSOPVSA-N
Pubchem ID :134611040

Safety of Danuglipron

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of Danuglipron

GPCR

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT06568731 Obesity PHASE1 COMPLETED 2024-12-18 Pfizer Clinical Research Unit ... More >>- New Haven, New Haven, Connecticut, 06511, United States Less <<
NCT06153758 Healthy Participants|Healthy S... More >>ubjects Less << PHASE1 COMPLETED 2024-09-30 Anaheim Clinical Trials, LLC, ... More >>Anaheim, California, 92801, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.80mL

0.36mL

0.18mL

9.00mL

1.80mL

0.90mL

18.00mL

3.60mL

1.80mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories